# Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

> **NCT07149363** · PHASE2 · RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 65 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** Durvalumab 50 MG/ML

## Key facts

- **NCT ID:** NCT07149363
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2029-02
- **Final completion:** 2031-02
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07149363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07149363, "Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07149363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*